Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentis plus Reduced Fluence PDT in Exudative AMD
NCT00455871Phase 2Unknown
- Sponsor
- Barnes Retina Institute
- Start
- Apr 2007
- Primary completion
- Oct 2010
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ranibizumab and verteporfin in exudative age-related macular degeneration (2 arms), sponsored by Barnes Retina Institute. Primary endpoints: Safety of the combination therapy at 24 months and Efficacy of the two timing regimens at 24 months. Status: unknown.
02
Drugs
ranibizumabverteporfin
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT00455871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00455871.